Moderna (NASDAQ:MRNA) Price Target Lowered to $108.00 at UBS Group

Moderna (NASDAQ:MRNA) had its price objective cut by UBS Group from $140.00 to $108.00 in a research note issued to investors on Thursday morning, Benzinga reports. They currently have a buy rating on the stock.

Other analysts also recently issued research reports about the stock. The Goldman Sachs Group decreased their price target on shares of Moderna from $178.00 to $139.00 and set a “buy” rating for the company in a research note on Monday, September 16th. Leerink Partners decreased their price target on shares of Moderna from $60.00 to $48.00 and set an “underperform” rating for the company in a research note on Tuesday, September 17th. William Blair reaffirmed a “market perform” rating on shares of Moderna in a research note on Thursday, June 27th. Sanford C. Bernstein assumed coverage on shares of Moderna in a research note on Thursday, October 17th. They set a “market perform” rating and a $55.00 price target for the company. Finally, Bank of America decreased their price target on shares of Moderna from $130.00 to $110.00 and set a “neutral” rating for the company in a research note on Friday, September 13th. Two research analysts have rated the stock with a sell rating, fourteen have issued a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $94.65.

Moderna Stock Up 0.5 %

Shares of NASDAQ:MRNA opened at $53.09 on Thursday. Moderna has a 1 year low of $52.26 and a 1 year high of $170.47. The business has a 50 day simple moving average of $67.68 and a two-hundred day simple moving average of $102.77. The firm has a market capitalization of $20.41 billion, a PE ratio of -3.45 and a beta of 1.66. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.09 and a quick ratio of 3.92.

Moderna (NASDAQ:MRNA) last announced its earnings results on Thursday, August 1st. The company reported ($3.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.47) by $0.14. Moderna had a negative return on equity of 21.35% and a negative net margin of 116.18%. The business had revenue of $241.00 million during the quarter, compared to analyst estimates of $128.41 million. During the same quarter in the previous year, the business earned ($3.62) earnings per share. The company’s revenue for the quarter was down 29.9% compared to the same quarter last year. On average, equities analysts predict that Moderna will post -9.94 EPS for the current year.

Insider Transactions at Moderna

In other news, Director Noubar Afeyan sold 15,000 shares of the company’s stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $119.96, for a total transaction of $1,799,400.00. Following the transaction, the director now directly owns 2,224,015 shares of the company’s stock, valued at approximately $266,792,839.40. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, Director Noubar Afeyan sold 15,000 shares of the business’s stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $119.96, for a total transaction of $1,799,400.00. Following the sale, the director now directly owns 2,224,015 shares of the company’s stock, valued at $266,792,839.40. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO James M. Mock sold 715 shares of the business’s stock in a transaction on Monday, October 7th. The shares were sold at an average price of $60.12, for a total transaction of $42,985.80. Following the sale, the chief financial officer now directly owns 9,505 shares in the company, valued at $571,440.60. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 18,184 shares of company stock valued at $2,037,931. Corporate insiders own 15.70% of the company’s stock.

Institutional Investors Weigh In On Moderna

Large investors have recently made changes to their positions in the stock. Ashton Thomas Private Wealth LLC purchased a new stake in shares of Moderna during the second quarter valued at $26,000. Cedar Wealth Management LLC boosted its holdings in Moderna by 45.0% in the first quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock valued at $31,000 after purchasing an additional 90 shares during the last quarter. Westside Investment Management Inc. purchased a new stake in Moderna in the first quarter valued at $32,000. Family Firm Inc. purchased a new stake in Moderna in the second quarter valued at $33,000. Finally, Bank & Trust Co purchased a new stake in Moderna in the second quarter valued at $36,000. 75.33% of the stock is owned by hedge funds and other institutional investors.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.